Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,502
  • Shares Outstanding, K 33,286
  • Annual Sales, $ 500 K
  • Annual Income, $ -39,830 K
  • EBIT $ -37 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.99
  • Price/Sales 26.91
  • Price/Cash Flow N/A
  • Price/Book 0.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.78
  • Most Recent Earnings $-0.17 on 11/06/25
  • Next Earnings Date 03/05/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3420 +9.82%
on 11/21/25
0.4213 -10.85%
on 12/11/25
+0.0233 (+6.61%)
since 11/12/25
3-Month
0.2935 +27.97%
on 09/18/25
0.4565 -17.72%
on 10/08/25
+0.0651 (+20.97%)
since 09/12/25
52-Week
0.2805 +33.90%
on 09/09/25
4.3000 -91.27%
on 01/08/25
-2.0244 (-84.35%)
since 12/12/24

Most Recent Stories

More News
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic...

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated...

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from...

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Provides Update on VYN202 Program

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics to Participate in March Investor Conferences

VYNE : 0.3756 (-7.28%)
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE : 0.3756 (-7.28%)

Business Summary

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

See More

Key Turning Points

3rd Resistance Point 0.4429
2nd Resistance Point 0.4283
1st Resistance Point 0.4019
Last Price 0.3756
1st Support Level 0.3609
2nd Support Level 0.3463
3rd Support Level 0.3199

See More

52-Week High 4.3000
Fibonacci 61.8% 2.7646
Fibonacci 50% 2.2903
Fibonacci 38.2% 1.8159
Last Price 0.3756
52-Week Low 0.2805

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar